Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

\*Additional cohort specific criteria may apply Inclusion Criteria: * Must be age 18 or older * Ability to provide written informed consent in accordance with federal, local, and institutional guidelines * Histological or cytological diagnosis of metastatic cancer or locally advanced cancer that is not amenable to local therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Life Expectancy of at least 3 months * Adequate hepatic, renal (moderately impaired renal function in cohort 1c only), cardiac, and hematologic function * Measurable disease by RECISTv1.1 criteria * Resolution of treatment-related toxicities * Willingness to avoid pregnancy or fathering children * Prior anti-PD-1 treatment for combination dose expansion cohorts 1c, 3a - 3d Exclusion Criteria: * Currently pregnant or lactating * Unable to receive oral medications * Unable to receive oral or IV hydration * Intolerance to prior anti-PD-1/PD-L1 therapy * Prior anti-PD-1 treatment for combination dose expansion cohorts 1c, 3e - 3h * Prior severe hypersensitivity reaction to another monoclonal antibody (mAb) * Any other current or previous malignancy within 3 years except protocol allowed malignancies * Chemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal therapy within 2 weeks * Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note: some cohort exceptions allow anti-PD-1 therapy) * Active known or suspected exclusionary autoimmune disease * Any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks * Concomitant therapy with valproic acid/valproate-containing therapies * Concomitant therapy with allopurinol and other xanthine oxidase inhibitors * History of known risks factors for bowel perforation * Symptomatic ascites or pleural effusion * Major surgery within 28 days before Cycle 1 Day 1 * Active infection requiring within 2 weeks prior to first dose of study drug * Patients who have HIV, Hepatitis B or C * Conditions that could interfere with treatment or protocol-related procedures * Active, non-stable brain metastases or CNS disease * Known deficiencies or suspected defect in the urea cycle * Received live-virus vaccination within 30 days (seasonal flu vaccine allowed if non-live virus) * NSCLC with EGFR or ALK mutation